Clinical Development Tracker
Drug Pipeline Tracker
Tracking every next-generation GLP-1, dual-agonist, and triple-agonist compound in clinical development. Phase data, published trial results, and anticipated regulatory timelines, all in one place.
Tracker facts for search and AI answers
What this pipeline tracker answers
Tracker scope
10 compounds, 111 mechanism/company/theme pages, and 79 direct-answer pages
The pipeline hub is the crawl path into compound, status, mechanism, and launch-timeline pages.
Late-stage signal
6 tracked compounds are currently marked Phase 3
Late-stage programs carry different commercial and access implications than early research assets.
Search intent coverage
8 best/next/company-battle pages are linked from this hub
These pages match comparison and approval-intent searches without consolidating detail pages.
Last review
April 11, 2026
Pipeline pages should be revisited when trial readouts, filings, or FDA decisions change the answer.
Explore the Pipeline
Mechanism lanes and company trackers
Mechanism tracker
Triple Agonists Obesity Pipeline: The Compounds That Matter Through 2028
Triple agonists are one of the most important lanes in obesity because they are trying to move beyond GLP-1 appetite suppression alone. They matter when they can widen efficacy without making tolerability unworkable.
Mechanism tracker
Oral GLP-1 Pipeline: Which Pill-Based Obesity Drugs Matter Most?
The oral GLP-1 pipeline matters because pills change the access equation. If one of these compounds truly scales, it can pressure pricing, widen adoption, and change how patients think about obesity medication.
Mechanism tracker
Amylin Obesity Pipeline: CagriSema, Amycretin, and the Satiety Layer
The amylin lane matters because it offers a different satiety logic from pure GLP-1. The real question is whether that difference becomes clinically and commercially meaningful enough to reshape the category.
Mechanism tracker
Non-Incretin Obesity Pipeline: The Most Interesting Alternatives to GLP-1
The non-incretin pipeline matters because the obesity market cannot stay an incretin monoculture forever. These assets are the best read on what the post-GLP-1 alternative landscape might look like.
Company tracker
Eli Lilly Obesity Pipeline: Retatrutide, Orforglipron, and What Comes After Zepbound
Eli Lilly has the most consequential obesity pipeline in the market because it is not just defending Zepbound. It is actively building the next commercial waves behind it.
Company tracker
Novo Nordisk Obesity Pipeline: CagriSema, Amycretin, and Novo's Second Act
Novo's pipeline matters because it is trying to prove the company still has a meaningful second act after the first GLP-1 blockbuster wave.
Company tracker
Pfizer Obesity Pipeline: Danuglipron, PF-3944, and the Recovery Question
Pfizer's obesity pipeline matters because the company still needs a credible path back into the category. The bigger question is no longer hype. It is recovery and relevance.
Company tracker
Roche Obesity Pipeline: CT-388, Petrelintide, and the Carmot Reset
Roche matters because it has enough scale to become a major obesity player fast if its current assets mature the right way.
Company tracker
AstraZeneca Obesity Pipeline: AZD6234, Elecoglipron, and the Broader Bet
AstraZeneca's pipeline matters because it is trying to assemble obesity relevance across multiple mechanisms instead of leaning on one obvious blockbuster candidate.
Company tracker
Viking Obesity Pipeline: Why VK2735 Still Matters So Much
Viking matters because VK2735 is still one of the clearest tests of whether a smaller company can hold strategic power in a market dominated by giants.
Pipeline theme
Phase 3 Obesity Pipeline: The Closest Drugs to Reshaping the Market
The Phase 3 obesity pipeline is where the market stops speculating and starts thinking about real launch sequences, pricing pressure, and prescribing behavior. These are the assets closest to changing what happens in clinics.
Pipeline theme
Phase 2 Obesity Pipeline: The Mid-Stage Drugs With Real Breakout Potential
The Phase 2 obesity pipeline is where a lot of the market's future winners and dead ends are still mixed together. This is the stage where a drug stops being a concept and starts proving whether it deserves late-stage money.
Direct Answers
What is it, when could it launch, and what comes next?
Answer page
What Is Retatrutide? Mechanism, Stage, and Why It Matters
Retatrutide is Eli Lilly's late-stage triple-agonist obesity drug candidate built around GLP-1, GIP, and glucagon signaling. It matters because it is still the clearest candidate to push the efficacy ceiling higher than the first GLP-1 wave.
Answer page
Retatrutide Launch Timeline: When Could It Actually Matter?
Retatrutide is still a late-stage pipeline asset, not a launched product. The realistic question is not whether it is important. It is how quickly Lilly can move from late-stage strength into a filing, approval, and real launch sequence.
Answer page
What Is Orforglipron? Why the First Big Oral Winner Matters So Much
Orforglipron is Eli Lilly's oral obesity drug candidate and the strongest pill-based obesity story in the market. It matters because pills can change access, pricing, adherence, and the size of the category faster than another injectable can.
Answer page
Orforglipron Launch Timeline: How Fast Could the Oral Obesity Story Scale?
Orforglipron's timeline is no longer just a science question. It is a rollout, pricing, supply, and payer-access question. That is why its launch matters more than most pipeline dates do.
Answer page
What Is Amycretin? Novo's Amylin Bet Explained
Amycretin is one of Novo Nordisk's most important next-wave obesity drug candidates. It matters because it represents Novo's attempt to build a second act beyond the first blockbuster GLP-1 wave.
Answer page
Amycretin Launch Timeline: When Could Novo's Next-Wave Bet Matter?
Amycretin is close enough to matter but not close enough to treat as a simple near-launch story. Its real timeline depends on how Novo sequences it against CagriSema and the rest of the franchise.
Answer page
What Is CagriSema? Filed Combo Story, Launch Odds, and Why It Matters
CagriSema is Novo Nordisk's filed obesity combination asset and one of the clearest near-term market events in the next wave. It matters because it is closer to launch than most pipeline names and could quickly affect pricing and access conversations.
Answer page
CagriSema Launch Timeline: How Soon Could Novo Turn It Into a Real Market Event?
CagriSema has one of the shortest distances between pipeline status and real launch. The remaining questions are now about decision timing, pricing, rollout, and whether the demand story feels truly strong.
Answer page
What Is VK2735? The Best Independent Obesity Asset Explained
VK2735 is Viking Therapeutics' flagship obesity drug candidate and the clearest test of whether a smaller company can still hold strategic power in a market dominated by giants.
Answer page
VK2735 Launch Timeline: How Far Can the Independent Challenger Go?
VK2735 is close enough to be taken seriously, but its timeline depends on more than clinical success. It also depends on whether Viking launches alone, partners, or exits into a larger platform.
Answer page
What Is Survodutide? The Glucagon-Angled Challenger Explained
Survodutide is a late-stage obesity drug candidate with a glucagon-linked mechanism profile that keeps it relevant in both weight-loss and liver-disease conversations. It matters because it is one of the few credible challengers that can still feel differentiated beyond plain appetite suppression.
Answer page
Survodutide Launch Timeline: When Could the Glucagon Story Turn Commercial?
Survodutide is close enough to matter, but not close enough to treat as a simple near-launch certainty. Its timeline depends on whether late-stage differentiation stays clear enough to justify a real commercial push.
Answer page
What Is MariTide? Why Amgen's Big Bet Still Draws So Much Attention
MariTide is Amgen's flagship obesity drug candidate and one of the few late-stage assets that still feels genuinely different. It matters because it gives Amgen a plausible way to matter in obesity without copying the market leaders exactly.
Answer page
MariTide Launch Timeline: How Soon Could Amgen Turn It Into a Real Threat?
MariTide is far enough along to matter, but the launch story still depends on whether Amgen can convert differentiation into a credible regulatory and commercial sequence. This is not a pure timing question. It is a readiness question.
Answer page
What Is Pemvidutide? Why This Mid-Stage Challenger Still Matters
Pemvidutide is a mid-stage obesity drug candidate that still matters because it sits in the overlap between weight-loss ambition and broader cardiometabolic relevance. It is one of the more credible mid-stage names that still feels worth tracking closely.
Answer page
Pemvidutide Launch Timeline: How Early Is Too Early to Talk Launch?
Pemvidutide is important enough to track, but still early enough that launch-timeline talk should stay disciplined. The real question is whether it can earn a clean late-stage path before anyone starts treating launch as imminent.
Answer page
What Is CT-388? Roche's Cleaner Incretin Story Explained
CT-388 is one of Roche's most important obesity assets and one of the cleaner incretin stories in the mid-stage field. It matters because it gives Roche a plausible lead asset in a category where credibility is still being assembled.
Answer page
CT-388 Launch Timeline: When Could Roche's Lead Asset Actually Matter?
CT-388 is not a near-launch story yet, but it is far enough along to matter strategically. The launch timeline depends on whether Roche can turn a clean mid-stage narrative into a confident late-stage development path.
Answer page
What Is Petrelintide? Roche's Amylin-Flavored Bet Explained
Petrelintide is one of Roche's important obesity assets in the amylin-pathway lane. It matters because it broadens Roche's strategy beyond a single incretin bet and keeps the satiety-layer story alive outside Novo.
Answer page
Petrelintide Launch Timeline: How Long Before Roche's Amylin Play Matters?
Petrelintide is important enough to track seriously, but it is still a medium-range launch story rather than an immediate one. The timeline depends on whether Roche turns it into a clear priority inside a crowded next-wave field.
Answer page
What Is Mazdutide? Why This Triple-Angled Program Still Deserves Attention
Mazdutide is a next-wave obesity and metabolic drug candidate that still matters because it keeps the triple-agonist conversation broader than one headline asset. It is a reminder that the ceiling story is not entirely Lilly's alone.
Answer page
Mazdutide Launch Timeline: How Close Is It to Real Market Relevance?
Mazdutide is important enough to track, but its launch timeline still depends on whether it stays strategically relevant in a triple-agonist field led by louder names. This is a credibility-and-priority question as much as a timing one.
Answer page
What Is Ecnoglutide? The Quiet Phase 3 Contender Explained
Ecnoglutide is a Phase 3 obesity drug candidate from Sciwind that matters because it keeps the late-stage GLP-1 field broader than the usual household names. It is one of the quieter contenders that still deserves a real read.
Answer page
Ecnoglutide Launch Timeline: Could the Quiet Phase 3 Story Get Louder Fast?
Ecnoglutide is late enough that launch timing is no longer hypothetical, but it still needs a clearer commercial story before people treat it like a real next-wave event. The timeline matters because the field is starting to bunch up.
Answer page
What Is PF-3944? Pfizer's Cleaner Long-Acting Obesity Bet
PF-3944 is a late-stage long-acting GLP-1 obesity drug candidate that matters because it gives Pfizer a cleaner re-entry story than some of its noisier oral efforts. It is one of the more straightforward recovery assets in the field.
Answer page
PF-3944 Launch Timeline: Can Pfizer Turn the Cleaner Story Into a Real Product?
PF-3944 is close enough to be part of the real launch conversation, but the timeline depends on whether Pfizer turns it into a central obesity priority instead of just another credible asset in a messy portfolio.
Answer page
What Is Aleniglipron? The Other Oral GLP-1 Worth Watching
Aleniglipron is an oral GLP-1 obesity drug candidate that still matters because the oral lane will not be a one-name story forever. It is one of the second-wave pill assets worth tracking behind the leader.
Answer page
Aleniglipron Launch Timeline: Does the Second-Wave Oral Field Still Have Room?
Aleniglipron is still early enough that its launch timeline depends as much on strategic survival as on raw development progress. The real question is whether the second-wave oral field still has room for another serious product story.
Answer page
What Is Danuglipron? Pfizer's Messier Oral Comeback Story
Danuglipron is Pfizer's oral GLP-1 obesity drug candidate, and it still matters because it represents the messy version of the oral-obesity comeback story. It is relevant not because it is clean, but because the sponsor scale still matters.
Answer page
Danuglipron Launch Timeline: Recovery Story or Real Route to Market?
Danuglipron still has a path, but its timeline is inseparable from the question of whether Pfizer can stabilize and simplify the story. This is not a clean countdown. It is a credibility test.
Answer page
What Is Elecoglipron? AstraZeneca's Earlier Oral Bet
Elecoglipron is AstraZeneca and Eccogene's oral GLP-1 obesity candidate. It matters because it helps show whether the oral lane will extend beyond the first leader and the biggest comeback names.
Answer page
Elecoglipron Launch Timeline: How Far Behind the Oral Leaders Is It?
Elecoglipron is still far enough back that its launch timeline is mostly a strategic watchlist question, not a near-market one. The key issue is whether it can stay relevant while the leaders reshape the lane first.
Answer page
What Is Cagrilintide? The Standalone Amylin Piece Behind CagriSema
Cagrilintide is Novo Nordisk's standalone amylin-pathway obesity asset, and it matters because it helps explain the broader satiety-layer strategy behind CagriSema and Novo's second-wave positioning.
Answer page
Cagrilintide Launch Timeline: Standalone Asset or Supporting Piece?
Cagrilintide's timeline depends less on whether it matters scientifically and more on whether Novo wants it to matter as a standalone product. That makes the launch path a portfolio-sequencing question as much as a clinical one.
Answer page
What Is AZD6234? AstraZeneca's Amylin Lane Explained
AZD6234 is AstraZeneca's selective amylin obesity asset, and it matters because it is one of the clearest reads on whether the amylin lane expands beyond Novo and Roche into a broader competitive field.
Answer page
AZD6234 Launch Timeline: Can AstraZeneca Turn the Amylin Bet Into a Real Product?
AZD6234 is important enough to track seriously, but its launch timeline still depends on whether AstraZeneca converts the asset from portfolio optionality into a clear product priority. The science is only part of the story.
Answer page
What Is Bimagrumab? The Body-Composition Alternative Explained
Bimagrumab is an obesity asset with a body-composition angle that matters because it represents one of the clearest alternatives to the idea that obesity treatment has to stay purely incretin-driven forever.
Answer page
Bimagrumab Launch Timeline: Could the Body-Composition Story Become Commercially Real?
Bimagrumab is important enough to watch, but its launch timeline depends on whether the market decides body-composition quality is commercially meaningful enough to support a real alternative lane. That makes the timing story unusually strategic.
Answer page
What Is Monlunabant? The CB1 Revival Bet Explained
Monlunabant is a CB1 inverse agonist obesity asset that matters because it keeps the idea of a non-incretin central-appetite alternative alive. It is one of the more interesting revival stories in the field.
Answer page
Monlunabant Launch Timeline: Is the CB1 Comeback Anywhere Near Real?
Monlunabant is still far enough away that launch talk should stay disciplined. The more important question is whether the CB1 comeback thesis becomes credible enough to justify thinking in launch terms at all.
Answer page
What Is Setmelanotide? The Proof That Precision Obesity Drugs Can Be Real
Setmelanotide is an approved precision-obesity drug for rare conditions, and it matters because it proves that obesity treatment does not have to be a one-size-fits-all incretin story. It is the clearest proof point for precision obesity medicine.
Answer page
Setmelanotide Launch Timeline: Already Approved, but How Broad Is the Real Obesity Lesson?
Setmelanotide is already approved, so the real timeline question is not launch. It is whether the precision-obesity lesson behind it broadens into a larger commercial and scientific category over time.
Answer page
What Is Lilly's Quintuple Agonist? The Highest-Ceiling Speculation in Obesity R&D
Lilly's quintuple agonist is a preclinical obesity program designed to stack GLP-1, GIP, glucagon, amylin, and calcitonin. It matters because it represents the outer edge of how aggressive receptor-stacking in obesity could become.
Answer page
Lilly Quintuple Agonist Launch Timeline: Not a Commercial Story Yet
There is no disciplined near-term launch timeline for Lilly's quintuple agonist yet. The real milestone is whether it graduates from striking concept to durable development priority.
Answer page
What Is NA-931 (Bioglutide)? The Quadruple Agonist Most People Have Barely Heard Of
NA-931, also called Bioglutide, is a quadruple-agonist obesity asset combining GLP-1, GIP, glucagon, and IGF-1. It matters because it is part of the industry's attempt to see how far multi-signal biology can go beyond first-wave incretins.
Answer page
NA-931 Launch Timeline: Early, Ambitious, and Still Unproven
NA-931 does not have a near-term launch timeline worth treating as reliable yet. It is still in the stage where proof of concept matters more than market-entry forecasting.
Answer page
What Is BI 3034701? Boehringer's Early Triple-Agonist Bet
BI 3034701 is an early triple-agonist obesity program from Boehringer and Gubra. It matters because it shows large companies still want exposure to the higher-ceiling triple-agonist lane beyond the obvious leaders.
Answer page
BI 3034701 Launch Timeline: A Long Runway Behind the Triple-Agonist Leaders
BI 3034701 is still far enough behind the leading obesity assets that launch talk should stay cautious. The real issue is whether it earns a distinct place in the triple-agonist field first.
Answer page
What Is Novo's Triple (UBT251)? The Underwatched Triple-Agonist Program
Novo's triple program, often referred to as UBT251, is a GLP-1, GIP, and glucagon obesity asset tied to Novo Nordisk. It matters because it shows Novo is still building optionality beyond its better-known amylin and GLP-1 stories.
Answer page
Novo Triple (UBT251) Launch Timeline: Still More Strategic Than Commercial
Novo's triple program does not belong in the near-launch conversation yet. The more realistic timeline question is whether it becomes central enough inside Novo's pipeline to accelerate meaningfully.
Answer page
What Is Kailera Triple? A Quiet Preclinical Entry in the Triple-Agonist Race
Kailera Triple is a preclinical GLP-1, GIP, and glucagon obesity program. It matters because even preclinical entrants tell you which mechanism lanes companies still think are worth chasing aggressively.
Answer page
Kailera Triple Launch Timeline: Still Deep in the Preclinical Zone
Kailera Triple is too early for responsible launch talk. The real timeline question is whether it advances fast enough to stay relevant in a lane that is already getting crowded.
Answer page
What Is AZD9550 Plus AZD6234? AstraZeneca's Mixed-Mechanism Combination Bet
AZD9550 plus AZD6234 is AstraZeneca's combination obesity program pairing GLP-1 and glucagon biology with amylin. It matters because combination logic may become one of the cleanest ways to keep pushing efficacy without relying on one compound alone.
Answer page
AZD9550 Plus AZD6234 Launch Timeline: Serious, but Not Simple
AZD9550 plus AZD6234 is further along than many speculative assets, but combination programs tend to carry extra execution risk. That means the timeline is real, but not clean.
Answer page
What Is GZR18? The Bi-Weekly GLP-1 That Could Matter More Than It Looks
GZR18 is a bi-weekly GLP-1 obesity asset from Gan & Lee. It matters because dosing convenience and persistence could become a more important differentiator as the obesity market matures.
Answer page
GZR18 Launch Timeline: A Format Story With Real Distance Left
GZR18 is interesting enough to watch, but not close enough to market to treat as a straightforward launch candidate yet. The format story matters, but it still needs a full product story behind it.
Answer page
What Is TG103? The GLP-1 Fc-Fusion Asset That Deserves More Attention
TG103 is a GLP-1 Fc-fusion obesity asset from CSPC Pharma. It matters because it represents another serious attempt to improve the delivery and durability side of obesity treatment without abandoning GLP-1 logic.
Answer page
TG103 Launch Timeline: More Real Than People Think, Still Not Simple
TG103 has a more serious development profile than many overlooked obesity names, but its launch path still depends on whether it can stand out in a crowded GLP-1 market.
Answer page
What Is NNC0174-0833? Novo's Early Amylin Follow-On
NNC0174-0833 is an early amylin-pathway obesity asset from Novo Nordisk. It matters because Novo is clearly not treating amylin as a one-product experiment.
Answer page
NNC0174-0833 Launch Timeline: Deep Bench Asset, Long Runway
NNC0174-0833 is still too early for a responsible launch forecast. Its significance today is strategic, not commercial.
Answer page
What Is Taldefgrobep? Biohaven's Muscle-Preservation Obesity Angle
Taldefgrobep is a myostatin-inhibitor obesity asset from Biohaven. It matters because the next obesity wave may be judged not just on weight loss, but on what happens to body composition along the way.
Answer page
Taldefgrobep Launch Timeline: A Body-Composition Story With Work Left
Taldefgrobep is still far enough from launch that the real question is not timing alone. It is whether the body-composition argument becomes strong enough to command attention.
Answer page
What Is Nimacimab? The Cleaner CB1 Rehabilitation Story
Nimacimab is a CB1 antibody obesity asset from Skye Bioscience. It matters because it offers a possible way to revisit the CB1 lane with a cleaner and more modern framing than the field had before.
Answer page
Nimacimab Launch Timeline: Interesting CB1 Redemption Story, Long Road
Nimacimab still has a long path before launch becomes a practical conversation. The first milestone is proving the CB1 redemption thesis strongly enough to matter.
Answer page
What Is HU6? The Metabolic-Energy Story That Still Stands Apart
HU6 is a mitochondrial uncoupler obesity asset from Rivus. It matters because it attacks obesity through energy expenditure logic rather than the usual satiety-and-glycemia framing.
Answer page
HU6 Launch Timeline: Different Enough to Matter, Early Enough to Stay Cautious
HU6 remains too early and too mechanism-sensitive for a clean launch forecast. Its next milestone is stronger validation, not commercial certainty.
Answer page
What Is S-309309? Shionogi's Quiet MGAT2 Obesity Bet
S-309309 is an MGAT2 inhibitor obesity asset from Shionogi. It matters because the obesity market still needs differentiated metabolic approaches that are not just more incretin stacking.
Answer page
S-309309 Launch Timeline: Credible Non-Incretin Story, Still Early
S-309309 is still too early for aggressive launch forecasting. The bigger question is whether the mechanism becomes relevant enough to justify a more serious commercial conversation.
Answer page
What Is Vutiglabridin? The Obesity Asset With One of the Most Unusual Mechanism Stories
Vutiglabridin is a PON1-modulator obesity asset from Glaceum. It matters because it represents one of the more unusual biological angles in the obesity field outside the incretin mainstream.
Answer page
Vutiglabridin Launch Timeline: Novel Biology, Long Conviction Cycle
Vutiglabridin is not a near-term launch story. Its path depends first on whether the field becomes convinced the mechanism deserves serious commercial attention.
Answer page
What Is DA-1726? NeuroBo's Oxyntomodulin Obesity Swing
DA-1726 is an oxyntomodulin obesity asset from NeuroBo. It matters because it keeps the glucagon-linked obesity story alive in a smaller-company format.
Answer page
DA-1726 Launch Timeline: Interesting Oxyntomodulin Story, Long Way to Go
DA-1726 is too early for a strong launch forecast. Its next job is proving that the oxyntomodulin story can compete with better-funded obesity programs.
Answer page
What Is BI 1820237? A Different Appetite-Control Story From Boehringer and Gubra
BI 1820237 is an NPY-Y2 agonist obesity asset from Boehringer and Gubra. It matters because it represents a different appetite-control strategy outside the standard incretin framing.
Answer page
BI 1820237 Launch Timeline: Early Appetite-Biology Bet, Long Distance Left
BI 1820237 is too early for a clean launch forecast. The program first has to prove that its appetite-biology angle is strong enough to deserve long-term development priority.
Answer page
What Is APHD-012? Aphaia's Gut-Nutrient Delivery Obesity Concept
APHD-012 is an obesity asset based on distal-jejunal dextrose delivery from Aphaia Pharma. It matters because it represents one of the more unusual gut-driven intervention ideas in the current field.
Answer page
APHD-012 Launch Timeline: Novel Gut-Biology Story, Very Early Commercial Read
APHD-012 is far too early and too novel for responsible launch forecasting. The first milestone is proving the concept belongs in the serious obesity conversation at all.
Answer page
What Comes After GLP-1 for Obesity? The Next Serious Waves
What comes after GLP-1 is not one thing. It is the combination of higher-ceiling receptor stacking, oral convenience, amylin-driven satiety strategies, and the few non-incretin assets that can actually become real products.
Answer page
Which Obesity Drugs Could Be Better Than Zepbound?
The drugs most often discussed as potentially better than Zepbound are the ones aiming for either a higher efficacy ceiling, a stronger satiety story, or a more convenient format. That short list starts with retatrutide, CagriSema, amycretin, and orforglipron for different reasons.
Answer page
Which Obesity Drugs Have the Best Launch Odds Through 2028?
The best launch-odds pages belong to assets that combine late-stage seriousness with sponsor scale and a believable demand story. Today that means CagriSema, orforglipron, retatrutide, amycretin, and a small handful of others.
Search Intent Pages
Best, next, and company battle pages
Pipeline theme
Best Obesity Drugs in Development: Which Pipeline Names Matter Most?
The best obesity drugs in development are the ones with a real combination of scientific credibility, strategic sponsor backing, and believable commercial impact. Right now that list starts with retatrutide, orforglipron, CagriSema, amycretin, VK2735, and survodutide.
Pipeline theme
Next Obesity Drugs to Be Approved: The Names Closest to Market
The next obesity drugs to be approved are the names already filed or sitting at the front of the late-stage queue. CagriSema is the clearest immediate approval-watch name, with retatrutide, orforglipron, amycretin, and VK2735 behind it in the serious next-wave group.
Pipeline theme
Best Oral Obesity Drugs in Development: Which Pill Programs Matter Most?
The best oral obesity drug in development right now is orforglipron. After that, the most relevant names are the second-tier oral and small-molecule challengers trying to stay visible behind the leader.
Pipeline theme
Most Promising Obesity Drugs After GLP-1: What Comes Next?
After the first GLP-1 wave, the most promising obesity drugs are not one single class. They are the best examples of four lanes: triple agonists, oral GLP-1s, amylin-pathway drugs, and the rare non-incretin asset that looks commercially real.
Pipeline theme
Obesity Drugs Closest to Launch: Which Pipeline Assets Could Matter First?
The obesity drugs closest to launch are the ones with either a filed status or a very short distance between Phase 3 completion and real commercialization. CagriSema and orforglipron are the clearest pages to watch first, with retatrutide close behind in strategic importance.
Pipeline theme
Eli Lilly vs Novo Nordisk Obesity Pipeline: Who Owns the Next Wave?
Lilly has the stronger next-wave momentum today. Novo has the deeper franchise-rebuild story. Both still matter because this is the defining obesity-company battle.
Pipeline theme
Pfizer vs Eli Lilly Oral Obesity Pipeline: Recovery Story vs Category Leader
Lilly leads the oral obesity race cleanly today. Pfizer still matters, but mainly as a recovery story rather than a leadership story.
Pipeline theme
Roche vs Viking Obesity Pipeline: Big-Pharma Depth vs Independent Focus
Roche has the broader obesity platform. Viking has the more concentrated and strategically explosive one. Which looks better depends on whether you value depth or focus.
For full regulatory context on the 2026 pipeline and the FDA 503A peptide review, see our 2026 State of Peptides & GLP-1 Regulation report.
Expected milestone timeline
Key anticipated regulatory and clinical milestones across all tracked compounds.
Compound directory
Explore every GLP-1 and next-generation weight loss compound currently in clinical development.
Oral Semaglutide 25mg/50mg (Rybelsus)
Novo Nordisk
Higher-dose oral semaglutide approaches injectable efficacy. Eliminates the need for injections, though still requires fasting before dosing.
CagriSema
Novo Nordisk
Combines two established mechanisms (GLP-1 + amylin) into a single injection. Outperformed semaglutide 2.4mg alone in head-to-head trial.
Retatrutide
Eli Lilly
Only triple agonist in advanced development. Activates GLP-1, GIP, and glucagon receptors simultaneously, targeting weight loss through three independent pathways.
Orforglipron
Eli Lilly
First oral small-molecule GLP-1 agonist with no food or water restrictions. Unlike oral semaglutide, does not require fasting before dosing. Could dramatically simplify GLP-1 therapy.
Survodutide
Boehringer Ingelheim
Strong dual benefit profile for both obesity and metabolic dysfunction-associated steatohepatitis (MASH). The glucagon component may increase energy expenditure beyond appetite reduction alone.
VK2735
Viking Therapeutics
Rapid weight loss in a short Phase 2 trial duration. Developing both injectable and oral formulations simultaneously from a smaller, more agile biotech company.
Mazdutide
Innovent Biologics (licensed from Eli Lilly)
China-first development strategy. Already approved in China for obesity, providing real-world efficacy and safety data while global development continues.
Ecnoglutide (XW003)
Sciwind Biosciences
Designed for monthly dosing, which could significantly improve patient adherence compared to weekly injections. Extended pharmacokinetic profile.
Pemvidutide
Altimmune
Focused development on the intersection of obesity and MASH (fatty liver disease). The glucagon component may provide liver-specific benefits beyond weight loss alone.
Amycretin
Novo Nordisk
Single-molecule GLP-1/amylin co-agonist with exceptionally rapid early weight loss. The oral formulation showed strong results in early data, potentially enabling a monthly oral pill.
Source reviewed
How to read pipeline claims
Readers searching for glp-1 obesity drugs pipeline need a direct answer first, then the details that could change the decision.
Answer the main query directly near the top, then expand with examples and caveats.
Add a small table or checklist so the page is easier to scan.
Link to the most relevant cost, safety, comparison, and next-step guides.
Questions this page should answer clearly
- What should readers know about glp-1 obesity drugs pipeline?
- Start with the plain answer, then add the caveat that changes the decision: cost, coverage, safety, provider oversight, pharmacy source, or whether the claim can be verified.
- What to know about glp-1 obesity drugs pipeline?
- Start with the plain answer, then add the caveat that changes the decision: cost, coverage, safety, provider oversight, pharmacy source, or whether the claim can be verified.
Frequently asked questions
What is a drug pipeline tracker?
What are the most promising weight loss drugs in development?
When will these new weight loss drugs be available?
What is the difference between GLP-1, GIP, and glucagon agonists?
Are compounded versions of these pipeline drugs available?
How often is this pipeline tracker updated?
Available Now: Compounded GLP-1 Medications
While these pipeline compounds are still in development, semaglutide and tirzepatide are available today through FormBlends with provider oversight and FDA-registered pharmacy sourcing.
Related Resources
Regulatory Status Tracker
FDA approval status and compounding legality for every compound.
The Science of GLP-1
How GLP-1 receptor agonists work and what the clinical data shows.
Orforglipron Guide
Deep dive into the oral GLP-1 that could change everything.
Clinical Research Library
Published studies on GLP-1 agonists, peptides, and weight management.
Content reviewed by the FormBlends Medical Advisory Team. Individual results vary. This page does not constitute medical advice.
Pipeline Information Disclaimer: The information on this page is compiled from publicly available clinical trial data, company press releases, and regulatory filings. It is provided for educational and informational purposes only. Drug development timelines, trial results, and regulatory outcomes are inherently uncertain and subject to change. Nothing on this page constitutes medical advice, a prediction of FDA approval, or a recommendation to use any medication.
Pipeline compounds listed here are investigational and not yet approved by the FDA for the treatment of obesity (unless specifically noted). They are not available through compounding pharmacies or any commercial source. Only FDA-approved medications that appear on the FDA drug shortage list can be legally compounded.
FormBlends does not manufacture, compound, or dispense medications. All medications offered through FormBlends are prescribed through independently licensed providers and dispensed by licensed 503A compounding pharmacies. Compounded medications are not FDA-approved and are not therapeutically equivalent to commercially available brand-name drugs. Always consult with a licensed healthcare provider before starting any medication.